NCT07223047 2026-03-17
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
Bristol-Myers Squibb
Phase 1/2 Recruiting
Bristol-Myers Squibb
Verastem, Inc.
Vanderbilt-Ingram Cancer Center
Centre hospitalier de l'Université de Montréal (CHUM)
Vanderbilt-Ingram Cancer Center